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Ранняя оценка медицинских технологий
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Россия, 630090, Новосибирск, пр. Академика Лаврентьева, 17
Проанализированы современные представления о проведении ранней оценки создаваемых 
медицинских технологий с целью разработки медицинских продуктов и услуг, обладающих 
дополнительной ценностью. Описаны способы определения коммерческой эффективности 
медицинских продуктов и услуг на ранних этапах их разработки и использования для сравнения с 
потенциальными конкурентами. Обзор может быть полезен лицам, вовлеченным в разработку 
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новых медицинских технологий и заинтересованным в повышении их инвестиционной 
привлекательности.
Ключевые слова: качество жизни, QALY, ранняя оценка медицинских технологий, 
инвестиционная привлекательность, разработка медицинских технологий.
In developed countries, health systems 
function according to the principles of value-
based health care, which means measuring the 
cost of medical products and services against the 
effectiveness of their impact on the quality of life 
of patients.
The world’s largest economies allocate 
significant resources to improving the efficiency 
of their health systems, including the development 
of new medical products and services. An 
outstanding trend in this area is the analysis of 
prospected products and services at early stages 
of their development, which may help improve 
their efficiency and reduce investment risks. This 
paper presents an analytical review of scientific 
research in this area and focuses on the rationales 
for creating medical technologies that have the 
potential for additional value.
In this paper, health technologies (HTs) are 
understood as methods of diagnostics, treatment 
and prevention of diseases and the rehabilitation 
of patients using vaccines, drugs, and medical 
devices, and surgical procedures and technologies 
designed to protect and preserve human health. 
Health technology assessment (HTA) is a common 
practice worldwide. This area of research has 
emerged because it could provide relevant 
information for choosing optimal ways to offer 
medical care within a limited health budget.
A definition and the general provisions of 
HTA can be found in the National Standards for 
the Evaluation of Medical Technologies approved 
by the Federal Agency for Technical Regulation 
and Metrology of the Russian Federation in 
2014. “Evaluation of a health technology is 
a comprehensive process of summarising 
information about a health technology, which 
aims at optimising decision-making and 
examines short- and long-term medical, social, 
economic and ethical aspects of the development, 
dissemination and application of a health 
technology; it is conducted using open, unbiased, 
systematic and sustainable procedures” (Federal 
Agency for Technical Regulation…, 2015). 
It should be noted that all HTs are subject to 
mandatory evaluation prior to registration even 
before they enter the market. The key difference 
is that a pre-registration evaluation is designed to 
assess the clinical efficacy and safety of an HT 
compared with a placebo or other drugs, which 
may not always reflect the interests of society, 
while the purpose of HTA is to estimate the 
added value of a new HT compared to the existing 
common clinical practice.
Earlier, a common criterion to determine 
the value or effect of an HT was the number of 
years of life saved. However, most of the present-
day health technologies do not always have a 
significant impact on life expectancy but can 
dramatically improve life quality, so a notion of 
the quality-adjusted life year (QALY) has been 
introduced. This indicator appeared in the UK 
and is now used in HTA in many countries around 
the world. In HTA, a variety of different clinical 
and economic indicators are used; among them is 
the incremental cost-effectiveness ratio (ICER), a 
statistical indicator used in clinical and economic 
analysis (CEA) to determine the relative cost-
effectiveness of medical interventions. The ICER 
is calculated as the ratio of the difference in 
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costs between two possible interventions to the 
difference in their effects; it shows the average 
additional costs that are necessary to obtain 
an additional unit of effect (value) during the 
intervention (application of an HT).
The costs of an HT (the ICER value) that 
the society considers acceptable to pay for 
obtaining an additional unit of effect (value) from 
this HT application is called the willingness-to-
pay (WTP) threshold. In other words, the WTP 
threshold determines the maximum allowable 
(threshold) ratio of additional health care costs to 
the unit of added medical effect (value). In recent 
years, the application of HTA has increased at 
the early stages of the development of medical 
products, and this practice is called early health 
technology assessment (early HTA).
The generally accepted definition of early 
HTA as “all methods used to inform industry and 
other stakeholders about the potential value of 
new medical products in development, including 
methods to quantify and manage uncertainty”, 
is given by IJzerman et al. (2017). The paper 
by Omelyanovsky (2014) contains a definition 
expressing the essence of this concept: “It is an 
analysis of the investment attractiveness of new 
technologies carried out at early stages of their 
development that is called early HTA.” Many 
studies worldwide are focused on the definition 
of the WTP threshold and calculation of QALYs. 
Thus, Yagudina et al. (2015) calculated this 
indicator for the Russian Federation following the 
methodology of the World Health Organisation 
with the official US dollar exchange rate set by 
the Central Bank and the purchasing power parity 
(PPP) of the rouble to the US dollar, as assessed 
by the World Bank. The authors concluded that 
the WTP threshold determined using the PPP 
is a more objective decision-making tool. In the 
study by Bezdenezhnykh et al. (2018), the WTP 
threshold is considered to be a tool for generating 
restrictive lists of HTs. Therefore, the definition 
and application of the WTP threshold in HTA will 
make it possible to optimise the use of authorised 
(registered) HTs.
Since early HTA is designed to determine 
the potential value of medical products, the 
implementation of the recommendations from the 
above authors will undoubtedly help increase the 
efficiency of new HTs development. It will be of 
particular interest to analyse the ICER values for 
one saved QALY and/or one saved year of life for 
the HTs that have already received both positive 
and negative feedback on inclusion in restrictive 
lists in Russia (Bezdenezhnykh et al., 2018). 
This indicator may be crucial for the investment 
attractiveness analysis of new HTs.
We realise that analyses and calculations for 
all large restrictive lists, for example, the list of 
vital and essential drugs, will be very costly and 
time consuming. Furthermore, the obtained result 
will be practically useless in HT development. 
When developing a new HT, the ICER calculation 
for one saved QALY should be done for the 
comparable drugs, those which the new HT will 
potentially compete with on the market. Thus, 
it is proposed to determine the WTP threshold 
for HTs with which the new medical product 
will compete. This will allow us to calculate the 
potential commercial effectiveness of a developed 
HT after its introduction to the market and more 
accurately assess the investment attractiveness of 
its development.
In Russia, there is no experience with 
applying the QALY and the methodology for 
calculating this indicator, which complicates the 
implementation of CEA. The world practice is 
to use quality of life questionnaires validated 
for QALYs (they contain a set of utility values 
that correspond to health conditions), which 
allows researchers to determine the indicator 
of effectiveness when conducting HTA. 
However, no quality of life questionnaire has 
been validated for use in Russia. This makes 
– 256 –
Oleg N. Shishatskiy. Early Assessment of Health Technologies
it difficult to use questionnaires in the Russian 
Federation to assess the quality of life and to 
carry out CEA. The paper by Makarova (2018) 
describes alternative approaches to obtaining 
utility values for universal questionnaires using 
forecasting (mapping) based on other indicators 
of the patient’s health status.
Using the QALY as an efficiency criterion 
is generally accepted when determining the cost-
effectiveness ratio of additional costs (ICER) and 
comparing them with the WTP threshold during 
HTA; however, the QALY often does not take 
into account a number of other socially important 
factors that are relevant to a patient and the society 
as a whole. For example, these factors may include 
relevance to the patient’s social group (children, 
working-age population, disabled people, etc.) 
and other characteristics of an HT (country of 
origin, degree of innovation, compliance with 
GMP criteria, etc.). A significant portion of new 
HTs that have high clinical efficacy and lead to a 
significant improvement in medical outcomes cost 
more than the WTP threshold. For this reason, 
patients will have limited access to desirable and 
effective HTs. Therefore, to evaluate the effect 
(value) in addition to a CEA, other criteria for 
evaluating HTs should be considered.
For this reason, the methodology of 
multi-criteria decision analysis (MCDA) has 
been introduced. It aggregates heterogeneous, 
seemingly unrelated criteria into a single 
indicator of HT value, which takes into account 
not only the CEA results but also various factors 
and their relative significance (weights or weight 
coefficients) and ensures that decisions are 
transparent and based on reproducible results 
obtained using this integral numeral indicator. 
In our opinion, application of the MCDA 
methodology for assessment at the early stages 
of development of particular HTs may be useful 
to determine their efficiency and relevance, 
especially in cases when the cost of a new HT 
exceeds the WTP threshold calculated on the 
basis of QALYs. MCDA is another method 
used to support decisions at early stages of 
medical product development. In particular, 
MCDA has been proposed to support portfolio 
decisions over a range of technologies where 
resources are allocated based on future value 
and development risk (Thokala et al., 2016). 
One of the main current trends in early HTA is 
the use of the ICER indicator based on QALYs 
and its comparison with the WTP threshold. In 
the Russian Federation, it is proposed to assess 
HTs using this indicator and compare it with the 
WTP threshold for a narrow group of comparable 
drugs, i.e., the products with which the potential 
HT will compete.
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